Vir Biotechnology (VIR) has recently seen a notable uptick, with a 2.6% daily gain contributing to a month-long stock return of approximately 26.7% and a year-to-date increase of 79.1%. Despite this recent surge, the company grapples with negative total shareholder returns over the past 3 and 5 years. Analysts currently assess the fair value of VIR at $20.78 per share, significantly above its recent closing price of $10.64, indicating that the stock may be undervalued due to optimistic growth expectations in its oncology pipeline. However, risks remain as potential clinical setbacks or regulatory delays could impact the company’s outlook.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/assessing-vir-biotechnology-vir-valuation-after-recent-share
